🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,153 results for “Ou” Clear

  1. RP-L102

    Rocket Pharmaceuticals B.V.

    Fanconi Anemia Complementation Group A

    phase 2 mab active

    3 trials

  2. Rabipur Polvere e solvente per soluzione iniettabile in siringa preriempita. Vaccino rabico (inattivato)., TICOVAC 0,25 ml per uso pediatrico Sospensione iniettabile in una siringa preriempita Vaccino (virus intero, inattivato) contro l'encefalite da zecca, AUTOLOGOUS PERIPHERAL BLOOD-DERIVED CD4+ T-CELLS CRISPR-EDITED AT THE CD40LG LOCUS, Infanrix hexa, Powder and suspension for suspension for injection. Diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomye

    Fondazione Telethon ETS

    X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)

    phase 2 small molecule active

    1 trial

  3. Raludotatug Deruxtecan

    Daiichi Sankyo

    Advanced/metastatic solid tumors including gynecological cancers (endometrial cancer, cervical cancer, and nonhigh- grade serous ovarian cancer) and genitourinary cancers (urothelial cancer and ccRCC)

    phase 2 small molecule active

    1 trial

  4. Rapamune 1 mg/mL oral solution

    Tour Hekla

    Lingual microcystic lymphatic malformations (LMLMs) are rare congenital vascular malformations, presenting as clusters of cysts filled with lymph fluid or blood. They are responsible for a heavy burden even with small well-limited lesions because of oozing, bleeding, infections, or even speech, chewing or breathing impairment. Pain and aesthetic prejudice are also frequently reported

    phase 2 small molecule active

    1 trial

  5. Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu- edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial

    Istituto Gentili S.r.l.

    NET, Neuroendocrine Tumor, Other SSTR-positive tumours, NETs retreated with PRRT, Pheochromocytomas and paragangliomas, Bronchopulmonary and other NETs

    phase 2 other active

    1 trial

  6. Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout Arthritis

    phase 2 small molecule active

    1 trial

  7. Recombinant Human Endostatin Injection

    The First People's Hospital of Lianyungang

    Locally Advanced Squamous Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  8. Recombinant human hyaluronidase + immune globulin intravenous

    Takeda

    Primary Immunodeficiency Diseases (PID)

    phase 2 mab completed

    1 trial

  9. Regimen Selection Phase Group 2

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  10. Retifanlimab (INCMGA00012), HOLOXAN 2000 mg, poudre pour usage parentéral, DOXORUBICINE ACCORD 2 mg/ml, solution pour perfusion

    The George Institute

    Adult patients with treatment-naïve surgically non-metastatic and resectable primary retroperitoneal, limbs and trunk wall undifferentiated pleomorphic sarcomas.

    phase 2 small molecule active

    1 trial

  11. Rimactan 300 mg hörð hylki., Moxifloxacin Tillomed 400 mg film coated tablets, LINEZOLID, RIMSTAR®, COMPRIMIDOS RECUBIERTOS CON PELÍCULA, Hidroxil B1-B6-B12 comprimidos recubiertos con película, Zyvoxid 600 mg Filmtabletten

    The George Institute

    Bacilliferous pulmonary tuberculosis

    phase 2 small molecule active

    1 trial

  12. Ritlecitinib tosilate, Placebo for pf-06651600-15, 100 mg, Placebo for pf-06651600-15, 50 mg, LORATADINE, Ritlecitinib Tosilate

    Pfizer Australia Pty Ltd

    CHRONIC SPONTANEOUS URTICARIA

    phase 2 small molecule active

    1 trial

  13. Routine Template-based lymphadenectomy

    The First People's Hospital of Lianyungang

    Lymph Node Dissection

    phase 2 other active

    1 trial

  14. Rozlytrek, Rozlytrek, Rozlytrek

    Hoffmann-La Roche

    Pediatric Solid tumors and primary central nervous system (CNS) tumors

    phase 2 small molecule active

    1 trial

  15. SELPERCATINIB, Selpercatinib, Selpercatinib, SELPERCATINIB, Selpercatinib

    Wuhan Createrna Science and Technology Co., Ltd

    Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors

    phase 2 small molecule active

    1 trial

  16. SHR-1210

    The First People's Hospital of Lianyungang

    Resectable Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  17. SIROLIMUS

    Pari Pharma GmbH

    Adult patients (men and women) (≥ 18 years of age) with cutaneous sarcoidosis involving the face

    phase 2 small molecule active

    1 trial

  18. SL-BUP

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Use Disorder (OUD)

    phase 2 small molecule active

    1 trial

  19. SNS-301

    Sensei Biotherapeutics

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 small molecule terminated

    1 trial

  20. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  21. SRM003

    Takeda

    Arteriovenous Graft

    phase 2 mab terminated

    1 trial

  22. SRM003

    Takeda

    Arteriovenous Fistula

    phase 2 mab completed

    1 trial

  23. SUL-238, Identical to test product except without active substance

    Sana Biotechnology

    Parkinson’s Disease

    phase 2 small molecule active

    1 trial

  24. Sacituzumab Tirumotecan in combination with tislelizumab

    The First People's Hospital of Lianyungang

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources